Immunome (IMNM) Other Non-Current Liabilities (2020 - 2023)

Immunome (IMNM) has 4 years of Other Non-Current Liabilities data on file, last reported at $1.3 million in Q4 2023.

• Quarterly Other Non-Current Liabilities rose 2061.29% year-over-year to $1.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.3 million (up 2061.29% YoY) and the FY2023 annual result came in at $1.3 million, up 2061.29% from the prior year.
• Other Non-Current Liabilities improved to $1.3 million in Q4 2023, from $122000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $7.1 million in Q3 2020 to a low of $12000.0 in Q4 2021.
• A 4-year average of $1.1 million and a median of $123000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 2061.29% in 2023, down 31.18% in 2023.
• Tracing IMNM's Other Non-Current Liabilities over 4 years: stood at $7.1 million in 2020, then slumped by 99.83% to $12000.0 in 2021, then surged by 416.67% to $62000.0 in 2022, then soared by 2061.29% to $1.3 million in 2023.
• The last three Other Non-Current Liabilities figures came in at $1.3 million (Q4 2023), $122000.0 (Q3 2023), and $62000.0 (Q4 2022), per Business Quant data.